---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-23-000028"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2023-07-27T23:59:59+00:00"
generated_at: "2026-06-13T00:27:48.347171+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AbbVie Q2 adj EPS $2.91 (-13.6%), rev $13.865B (-4.9%); raises FY adj EPS guidance to $10.90-$11.10

## Summary
- GAAP diluted EPS $1.14 (+123.5% YoY); adjusted diluted EPS $2.91 (-13.6% YoY); includes $0.15 IPR&D impact.
- Total net revenues $13.865B (-4.9% reported; -4.2% operational). Immunology $6.813B (-5.5%); Humira -25.2% to $4.012B.
- Skyrizi +50.4% to $1.883B; Rinvoq +55.1% to $918M. Neuroscience +13.6% to $1.885B; Vraylar +33.9%.
- Raised FY2023 adjusted diluted EPS guidance from $10.57-$10.97 to $10.90-$11.10; includes $0.23 IPR&D year-to-date.

## SEC filing metadata
- accession: 0001551152-23-000028
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2023-07-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000028/0001551152-23-000028-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000028/abbv-20230727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-23-000028
- JSON: https://secwatch.observer/filing/0001551152-23-000028.json
- Plain text: https://secwatch.observer/filing/0001551152-23-000028.txt

## Key facts
- Earnings Releases
  AbbVie Inc. reported the second quarter ended June 30, 2023 results: revenue $13.865 Billion, EPS $1.14. Guidance raised.
  - Period: the second quarter ended June 30, 2023
  - Revenue: $13.865 Billion
  - EPS: $1.14
  - Guidance: raised
  - Result: reported results
  source text: PRESS RELEASE AbbVie Reports Second-Quarter 2023 Financial Results • Reports Second-Quarter Diluted EPS of $1.14 on a GAAP Basis, an Increase of 123.5 Percent; Adjusted Diluted EPS of $2.91, a Decrease of 13.6 Percent; These Results Include an Unfavorable Impact of $0.15 Per Share Related to Acquired IPR&D and Milestones Expense • Delivers Second-Quarter Net Revenues of $13.865 Billion, a Decrease of 4.9 Percent on a Reported Basis and 4.2 Percent on an Operational Basis • Second-Quarter Global Net Revenues from the Immunology Portfolio Were $6.813 Billion, a Decrease of 5.5 Percent on a Reported Basis, or 5.0 Percent on an Operational Basis; Global Humira Net Revenues Were $4.012 Billion; Global Skyrizi Net Revenues Were $1.883 Billion; Global Rinvoq Net Revenues Were $918 Million • Second-Quarter Global Net Revenues from the Hematologic Oncology Portfolio Were $1.478 Billion, a Decrease of 10.4 Percent on a Reported Basis, or 9.8 Percent on an Operational Basis; Global Imbruvica Net
  evidence_url: https://www.sec.gov/Archives/edgar/data/1551152/000155115223000028/0001551152-23-000028-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.